Status: Recruiting
18F FES-PET/MRI for Tailoring Treatment of Luminal A and Lobular Breast Cancer
Study hypothesis is that combining the advantages of hybrid PET/MRI and the high sensitivity/specificity of 16-alpha-18F-fluoro-17-beta-estradiol(FES), a radiolabeled form of estrogen binding to functionally active ER, the investigators could obtain a reliable, non-invasive, operator-independent, one-stage imaging method for staging LumA and ER-positive Lobular tumours.
Participants needed: 119
Trial details
Phase: Phase 2Age: 18+Biological sex: FemaleType: InterventionalSponsor: Università Vita-Salute San RaffaeleUpdated: Jun 12, 2026Locations: 1
Eligibility criteria
Female patients, age>= 18 yrs, diagnosed with primary or advanced breast cancer [+3]
ER-negative tumors [+6]